Regarding full details of the resolutions, a referral is made to the notice convening the AGM and the complete proposals. The notice convening the AGM and the complete proposals are available at the company's website, www.sedanamedical.com.

Adoption of the income statements and the balance sheets

The meeting resolved to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2022.

Allocation of the results

The meeting resolved, in accordance with the board's proposal, that no dividend shall be paid for the financial year 2022 and that the company's available funds shall be balanced in a new account.

Discharge from liability

The general meeting discharged each who had held the position as CEO or board member from personal liability during the financial year 2022.

Board and auditors

The meeting resolved, in accordance with the nomination committee's proposal, that the board be composed of five (5) directors with no deputies and that the company have one (1) auditor with no deputy.

The meeting resolved, in accordance with the nomination committee's proposal, to re-elect Claus Bjerre, Hilde Furberg, Ola Magnusson, Christoffer Rosenblad and Eva Walde as ordinary board members. Claus Bjerre was elected as the new chairman of the board. Thomas Eklund had declined re-election

The meeting resolved, in accordance with the nomination committee's proposal, to re-elect the registered accounting firm Öhrlings PricewaterhouseCoopers AB as the company's auditor.

The meeting resolved, in accordance with the nomination committee's proposal, that fees to the directors shall be paid in the amount of SEK 1,760,000, of which SEK 625,000 to the chairman of the board and SEK 250,000 to each of the other directors elected by the general meeting. In addition, remuneration to members of the audit committee shall be paid in the amount of SEK 75,000 to the chairman of the audit committee and SEK 30,000 to each of the other (currently two (2)) members of the committee.

The meeting resolved, in accordance with the nomination committee's proposal, that that remuneration to the auditor be paid in accordance with approved invoices.

Guidelines for remuneration to senior executives

The meeting resolved, in accordance with the board's proposal, to adopt guidelines for remuneration to senior executives.

Issue authorization

The meeting resolved, in accordance with the board's proposal, to authorize the board to, at one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders' preferential rights, resolve upon new share issues. By new share issue resolutions made by exercise of the authorization, with deviation from the shareholders' preferential rights, the company's share capital may not be increased by an amount exceeding ten (10) per cent of the share capital in the company at the time when the authorization is exercised for the first time.

_________________

For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Johan Spetz, CFO, +46 (0)730 36 37 89
ir@sedanamedical.com

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden.